Young doctor pursues nuclear medicine to improve cancer treatment Chia sẻ | FaceBookTwitter Email Copy Link Copy link bài viết thành công
16/01/2021 11:00 GMT+7
Doctor Mai Hong Son, who works at the 108 Military Central Hospital in Hanoi, did not choose nuclear medicine in the first place yet 10 years of hard work and diligent learning have turned him into an award-winning expert and researcher in the field.
Doctor Mai Hong Son, who works at the 108 Military Central Hospital in Hanoi, did not choose nuclear medicine in the first place yet 10 years of hard work and diligent learning have turned him into an award-winning expert and researcher in the field.
Loading video.
VIDEO: Alexander Stremitzer discusses the legal implications for physicians of following artificial intelligence advice in this new video from The Journal of Nuclear Medicine. view more
Credit: Video created by Alexander Stremitzer and Eidgenössische Technische Hochschule Zürich Center for Law and Economics.
Reston, Virginia Physicians who follow artificial intelligence (AI) advice may be considered less liable for medical malpractice than is commonly thought, according to a new study of potential jury candidates in the U.S. Published in the January issue of
The Journal of Nuclear Medicine (JNM). The study provides the first data related to physicians potential liability for using AI in personalized medicine, which can often deviate from standard care.
Methodology for evaluation of tumor cell density (TCD) and allocation of radiotherapy response categories. (A) Virtual graticule of approximately 300 points applied to tumor area on a digital H&E section. (B) Demonstration of TCD point scoring. (C) Box and whisker plot to show the relationship between ΔTCD and American Joint Committee on Cancer (AJCC) Tumour Regression Grade System (TRG). (D, E) Allocation of three radiotherapy response groups according to change in TCD (ΔTCD) for short-course radiotherapy (SCRT) (D) and long-course chemoradiotherapy (LCRT) (E). The Kruskall-Wallis test was used for statistical comparisons. Image courtesy of BMJ
Share this article
WASHINGTON, Dec. 17, 2020 /PRNewswire/ Recent articles in
Experimental Biology and Medicine highlight new advances in COVID-19 biology and treatment. In an effort to provide the scientific community with important information on COVID-19, at the rapid pace required to protect our global health care workers and bring useful therapies to end the pandemic, manuscripts are being handled at an accelerated rate. To accomplish this, our EBM Editor-in-Chief is handling all COVID-19 manuscripts to make sure they receive a thorough but accelerated review. The Publisher of EBM, SAGE, is making sure that accepted COVID-19 manuscripts are processed rapidly, immediately available via On-line First, and are open access. EBM will continue to inform the scientific community and the public of these published articles through press releases.
PET imaging tracer proves effective for diagnosing and managing rare CNS B-cell lymphoma medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.